Treatment Information

Back

Melanoma treatment details. Chemotherapy, Immunotherapy.

Beth Israel Deaconess Medical Center, Boston, Mass, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Boston, Mass
Treatments:Chemotherapy, ImmunotherapyHospital:Beth Israel Deaconess Medical Center
Drugs:Journal:Link
Date:Oct 2002

Description:

Patients: This Phase II study involved 48 patients with metastatic melanoma.

Treatment: The treatment consisted of chemotherapy (cisplatin, vinblastine, temozolomide) and immunotherapy (interleukin 2 and interferon-alpha 2B).

Toxicity: Significant toxicities included 2 deaths from cardiac events. Grade 3-4 toxicities included neutropenia, thrombocytopenia, renal insufficiency, and nausea/vomiting.

Results: The overal median survival was 7.5 months.

Support: The study was supported by grants from Amgen, Chiron, and Schering Plough. Chiron markets or manufactures interleukin-2 and Schering markets or manufactures interferon-alpha2B and temozolomide.

Correspondence: Michael B. Atkins, MD





Back